Bita Fakhri, Bita Fakhri, MD, MPH

Financial relationships

  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Abbvie
    Topic:
    CLL
    Date added:
    03/29/2024
    Date updated:
    03/28/2025
    Relationship end date:
    03/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    AstraZeneca
    Topic:
    CLL
    Date added:
    03/29/2024
    Date updated:
    03/28/2025
    Relationship end date:
    03/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Beigene
    Topic:
    CLL
    Date added:
    03/29/2024
    Date updated:
    03/28/2025
    Relationship end date:
    03/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    TG Therapeutics
    Topic:
    CLL
    Date added:
    03/29/2024
    Date updated:
    03/28/2025
    Relationship end date:
    03/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Adaptive
    Topic:
    CLL
    Date added:
    03/29/2024
    Date updated:
    03/28/2025
    Relationship end date:
    03/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Loxo/Lilly
    Topic:
    CLL
    Date added:
    03/29/2024
    Date updated:
    03/28/2025
    Relationship end date:
    03/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Pharmacyclics
    Topic:
    CLL
    Date added:
    03/29/2024
    Date updated:
    03/28/2025
    Relationship end date:
    03/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    BMS/Juno
    Topic:
    CLL
    Date added:
    03/29/2024
    Date updated:
    03/28/2025
    Relationship end date:
    03/31/2024
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Genentech
    Topic:
    Consultancy/Advisory Board/Steering Committees​
    Date added:
    03/28/2025
    Date updated:
    03/28/2025
  • Attribution:
    Self
    Type of financial relationship:
    Professional Services
    Ineligible company:
    Janssen
    Topic:
    Consultancy/Advisory Board/Steering Committees​
    Date added:
    03/28/2025
    Date updated:
    03/28/2025

Pages

Return to 2025 National Summit on Hematologic Cancers